Lanean...
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
The development of checkpoint inhibitors has changed the treatment paradigm for cancer. Checkpoint inhibitors nivolumab, pembrolizumab, and cemiplimab target programmed death-1 (PD-1), whereas durvalumab, avelumab, and atezolizumab target PD-ligand 1. Ipilimumab targets cytotoxic T lymphocyte–associ...
Gorde:
| Argitaratua izan da: | South Med J |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Lippincott Williams & Wilkins
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7587235/ https://ncbi.nlm.nih.gov/pubmed/33140115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14423/SMJ.0000000000001166 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|